Dr Emma Searle Previews MajesTEC-2 Data to Be Presented at ASH 2022

This is an exciting time to be working in the myeloma space, said Emma Searle, PhD, consultant hematologist, The Christie Hospital NHS Foundation Trust. Searle will be presenting data from a part of the MajesTEC-2 study on teclistamab in combination with daratumumab and lenalidomide in patients with relapsed multiple myeloma at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition, being held December 10-13, 2022, in New Orleans, Louisiana.

Transcript

What will be the most important takeaways from the MajesTEC-2 study data presented at the ASH Annual Meeting and Exposition?

The key points that we've learnt from the MajesTEC-2 data, in addition to what we had already been learning from MajesTEC-1, are that teclistamab is a very powerful antimyeloma therapy with a novel mechanism of action that has the potential to induce rapid and deep responses in patients with relapsed multiple myeloma. The patient population in MajesTEC-2 was less heavily pretreated than the patient population in MajesTEC-1, and we're seeing very high overall response rates in this combination of near to 94% across the 2 different dosing schedules. Those responses appear to deepen over time. This isn't mature data, but I think the promise is certainly that.

What data are you looking forward to seeing at ASH?

For me as a phase 1 trialist, it's always looking at the novel agents coming through in that space. This is a great time to be a clinical trialist in myeloma. We've got a large number of exciting agents with novel targets. The immunotherapies, obviously, are particularly exciting. And myeloma is still not a curable condition, but I think we're really making progress now in terms of discovering alternative methods of treating myeloma with the potential to achieve deep and durable responses. This really is an exciting time to be working in this space.